EGFR and non-small cell lung carcinoma: Although a preclinical study showed that afatinib could inhibit EGFR T790M and block the growth of non-small cell lung cancer (NSCLC) cell lines harboring T790M mutations [17], the clinical trial did not show the overall survival benefit in patients after failure of platinum doublet and first-generation EGFR TKIs [18].